Gritstone Oncology Announces Appointment of Mike Forcht, as Senior Vice President of Human Resources to Support Vision for Growth
March 11, 2019 at 01:30 pm IST
Share
Gritstone Oncology, Inc.ay announced that Mike Forcht, Ed.D., M.B.A., has joined the company as senior vice president of Human Resources, bringing more than 20 years of global management experience. Mike Forcht, Ed.D., M.B.A., joins Gritstone from ADLINK Technology, where he was the vice president of Human Resources (HR). In this capacity, he provided global HR leadership, including overseeing the strategic direction and implementation of talent acquisition and development for this technology leader. From 2014 to 2016, Mr. Forcht was the vice president of HR at Intematix, a technology company that had been ranked among Deloitte’s Technology Fast 500 list for several years in a row. Previously, he was the senior director of HR Operations and Talent Development at SanDisk where he supported a global R&D organization. From 2009 to 2012, Mr. Forcht was the Vice President of HR for Applied Signal Technology, a full-service intelligence, surveillance, and reconnaissance (ISR) provider bringing cutting-edge science and engineering together to enhance global security. Mr. Forcht also held leadership roles at Loral Space Systems, Intuit, Genesys Telecommunications, 3Com Corporation and Apple Computer. Mr. Forcht has an Ed.D. in organizational leadership from the University of San Francisco and an M.B.A. from San Jose State University.
Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.
GRITSTONE BIO, INC. 
